Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Revenue of Evoke Pharma, Inc. (EVOK)
Revenue in 2023 (TTM): $5.18 M
According to Evoke Pharma, Inc.'s latest financial reports the company's current revenue (TTM) is $5.18 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Evoke Pharma, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $5.18 M | $4.98 M | $-7,430,890 | $-7,792,295 | $-7,792,295 |
| 2022 | $2.51 M | $2.14 M | $-7,724,130 | $-8,224,130 | $-8,162,123 |
| 2021 | $1.62 M | $1.29 M | $-8,143,032 | $-8,537,952 | $-9,029,387 |
| 2020 | $23.02 K | $-63,692 | $-13,041,677 | $-13,154,671 | $-13,261,993 |
| 2019 | $ | $ | $-7,154,453 | $-7,125,655 | $-7,096,857 |
| 2018 | $ | $ | $-8,448,077 | $-7,566,080 | $-7,566,080 |
| 2017 | $ | $ | $-10,225,333 | $-12,229,512 | $-12,229,512 |
| 2016 | $ | $ | $-11,142,040 | $-10,748,531 | $-10,748,531 |
| 2015 | $ | $ | $-11,515,143 | $-12,121,463 | $-12,121,463 |
| 2014 | $ | $ | $-13,139,847 | $-13,247,681 | $-13,247,681 |
| 2013 | $ | $ | $-2,594,580 | $-2,836,465 | $-2,836,465 |
| 2012 | $ | $ | $-2,000,736 | $-2,017,528 | $-2,017,528 |
| 2011 | $ | $ | $-2,403,872 | $-2,401,244 | $-2,401,244 |